Next Article in Journal
Codon-Precise, Synthetic, Antibody Fragment Libraries Built Using Automated Hexamer Codon Additions and Validated through Next Generation Sequencing
Next Article in Special Issue
Purpose-Oriented Antibody Libraries Incorporating Tailored CDR3 Sequences
Previous Article in Journal
Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy
Article Menu

Export Article

Open AccessArticle
Antibodies 2015, 4(2), 71-87; doi:10.3390/antib4020071

A Monoclonal Antibody to Human DLK1 Reveals Differential Expression in Cancer and Absence in Healthy Tissues

1
Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich), Vladimir-Prelog-Weg 2, CH-8093 Zurich, Switzerland
2
Philochem AG, Libernstrasse 3, CH-8112 Otelfingen, Switzerland
*
Author to whom correspondence should be addressed.
Academic Editor: Ahuva Nissim
Received: 18 November 2014 / Revised: 19 March 2015 / Accepted: 8 April 2015 / Published: 16 April 2015
(This article belongs to the Special Issue Antibody Gene Libraries)
View Full-Text   |   Download PDF [1203 KB, uploaded 16 April 2015]   |  

Abstract

There is considerable interest in the characterization of novel tumor-associated antigens that lend themselves to antibody-mediated pharmacodelivery strategies. Delta-like 1 homolog protein (DLK1), which exists both as transmembrane protein and in soluble form, shows a restricted pattern of expression in healthy organs, while being overexpressed in some tumors. We have generated a human antibody specific to DLK1 using phage display technology. This reagent was used for a comprehensive characterization of DLK1 expression in freshly frozen sections of normal human adult tissues and of xenografted human tumors. DLK1 was virtually undetectable in most organs, except for placenta which was weakly positive. By contrast, DLK1 exhibited a moderate-to-strong expression in 8/9 tumor types tested. Our analysis shed light on previous conflicting reports on DLK1 expression in health and disease. The study suggests that DLK1 may be considered as a target for antibody-mediated pharmacodelivery strategies, in view of the protein’s limited expression in normal tissues and its abundance in the interstitium of neoplastic lesions. View Full-Text
Keywords: DLK1; antibody; phage display; immunostaining; small immune protein (SIP); pharmacodelivery; tumor targeting DLK1; antibody; phage display; immunostaining; small immune protein (SIP); pharmacodelivery; tumor targeting
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Bujak, E.; Ritz, D.; Neri, D. A Monoclonal Antibody to Human DLK1 Reveals Differential Expression in Cancer and Absence in Healthy Tissues. Antibodies 2015, 4, 71-87.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top